CardioDynamics' CEO, Michael K. Perry, Speaks to Investors.Business Editors/Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--June 20, 2003 Company announces an online interview with Michael K. Perry, chief executive officer of CardioDynamics (Nasdaq: CDIC CDIC Chronic Diseases In Canada (journal) CDIC Canadian Deposit Insurance Corporation CDIC Carbon Dioxide Information Center CDIC Center for Data Intensive Computing (BNL) ), the innovator and leader of Impedance Cardiography Impedance cardiography is a hemorheology technique of using sensors to detect the properties of the blood flow in the Thorax. Introduction Impedance cardiography (ICG), also referred to as thoracic electrical bioimpedance (TEB) and electrical impedance plethysmography (ICG ICG indocyanine green. ) technology. The program recaps the Company's recently announced second quarter, 2003 financial results and accomplishments in the quarter.
CEO Guest: Michael K. Perry, CEO of CardioDynamics
Interviewer: Francis Gaskins, Editor
To Access: RealAudio: http://gaskinsco.com/cdic5.ram
Windows Media: http://mmslb.eonstreams.com/gaskins/cdic5.wma
About CardioDynamics: CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of breakthrough medical technology called Impedance Cardiography (ICG). The Company's primary products, the BioZ(R) Systems, are being used by leading physicians around the world to help battle the number one killer of men and women -- cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease . Partners include GE Medical Systems Information Technologies, Philips Medical Systems, and Vasomedical. The worldwide market potential for BioZ products is estimated to be $5 billion and an additional $800 million in recurring annual revenue for disposables. For additional information or to request an investor package, please refer to the company's Web site at www.cdic.com. Forward-Looking (Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. ) Statement: Except for the historical and factual information contained herein, this press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. , such as estimated cardiovascular and ICG industry prospects, market size, potential, growth and penetration rates, the accuracy of which is necessarily subject to uncertainties and risks including the Company's sole dependence on the BioZ product line, and various uncertainties characteristic of early growth companies, as well as other risks detailed in the Company's filings with the SEC, including its 2002 Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. . The Company does not undertake to update the disclosures contained in this press release. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion